Address: Hospital: Acc No. (Incident Isolate): Acc No. (Subseq Isolate	State ID: Date o	f Incident Specimen Collection	(mm-dd-yyyy): Surveillance Officer Initials
Hospital: Hospital: Hospital: Hospital:	• • • • • • • • • • • • • • • • • • • •	CANDIDEMIA 202	24 CASE REPORT FORM
Hospital:	atient name:		Medical Record No.:
Clay State Clay Code Acc No. (incident isolate):		MI)	
Cap, Sale Cap, Code Acc No. (subseq isolate): Address type: Cap Code Cap Co			• •
Address type: Residential 2 Post office 3 Long-term care facility 4 Corrections 5 Military 6 Homeless 7 Other 8 Insufficient 9 Phone no.: (
Check if not a case:	, ,,	(Zip Code)	Acc No. (subseq isolate):
Reason not a case: Reason no	.ddress type: □ Residential 2 □ Post office 3 □	Long-term care facility 4 □Corre	ections 5 Military 6 Homeless 7 Other 8 Insufficient 9 Missing
Check if not a case: Reason not a case: Description of catchment area Duplicate entry Not candidemia Unable to verify address Other (specify): SURVEILLANCE OFFICER INFORMATION 1. Date reported to EIP site: Identified through audit? 1 Yes 0 No 2. Date review completed: 1 Yes 0 No 3. Was case first Identified through audit? 1 Yes 0 No 2. Date review completed: 1 Yes 0 No 3. If yes, enter state 3. Unavailable? 1 Yes 0 No 3. If yes, enter state 3. Unavailable 3. The county: 3. Patient ID: 3. Date of birth (mm-dd-yyyy): 4. Age: 1. Date of birth (mm-dd-yyyy): 14. Age: 15. Sex: 16. Weight: 18. BMI: (record only if ht. and/or wt. is available) 3. Date of lincident Apply): 3. Date of Incident Apply): 3. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy): 4. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy): 5. Sex: 5. Previous candidemie pisode? 6. CRF status: 7. Complete 8. BMI: (record only if ht. and/or wt. is available) 8. BMI: (record only if ht. and/or wt. is available) 8. BMI: (record only if ht. and/or wt. is available) 9. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy): 9. Date of	'hone no.: ()		
Reason not a case: Out of catchment area Duplicate entry Not candidemia Unable to verify address Other (specify): SURVILLANCE OFFICER INFORMATION 3. Was case first identified through audit? 1 Yes 0 No No 1 Yes 0 No 1 Yes 0 No 2 Pending 3 Candida abbicans (CA) 1 Yes 0 No No No No No No No			
SURVEILLANCE OFFICER INFORMATION 1. Date reported to EIP site: 3. Was case first identified through audit? 1 Yes 0 No 9 Unknown 1 Complete is identified through audit? 1 Yes 0 No 9 Unknown 2 Dending 3 Chart Unavailable 1 Yes 0 No 9 Unknown 2 Dending 3 Chart Unavailable DEMOGRAPHICS 8. State ID:	——————————————————————————————————————		
1. Date reported to EIP site: identified through audit?	leason not a case: Out of catchr	ment area Duplicate entry No	ot candidemia Unable to verify address Other (specify):
Identified through audit? 1 Yes 0 No 9 Unknown 1 Complete International Inte	SURVEILLANCE OFFICER INFOR	RMATION	
2. Date review completed:	i	identified through audit? $ig _1 igcap_{Ye}$	es 0 No 9 Unknown 1 Complete initials:
DEMOGRAPHICS		4. Isolate available? IDs:	yes, enter state
8. State ID:			
9. Patient ID:	DEMOGRAPHICS		
12. Lab ID where positive culture was identified: 13. Date of birth (mm-dd-yyyy): 14. Age:	3. State ID:	10. State:	11. County:
13. Date of birth (mm-dd-yyyy): 1	. Patient ID:		
13. Date of birth (mm-dd-yyyy): 1	2 Lab ID whore positive sulture	was identified.	
1 days 2 mos 3 yrs Male Female			
Ibs. oz. OR			
Race (check all that apply): 20. Ethnic origin: 1 Hispanic/Latino 3 Mitter 2 Not Hispanic/Latino 3 Mitter 3 Mitter 3 Mitter 4 Miter 3 Mitter 4 Miter 5 Mitter 6 Mit	.6. Weight:		
19. Race (check all that apply): American Indian/Alaska Native			
American Indian/Alaska Native	kg	cm L	Unknown available) Unknow
American Indian/Alaska Native	.9. Race (check all that apply):		20. Ethnic origin:
Asian		☐Native Hawaiian/Pacif	
21. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy):	☐Asian	□White	2 □Not Hispanic/Latino
21. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy):	☐Black/African American	□Unknown	9 □Unknown
21. Date of Incident Specimen Collection (DISC) (mm-dd-yyyy):	ABORATORY DATA		
22. Location of Specimen Collection: Hospital Inpatient		lection (DISC) (mm-dd-1444):	
Hospital Inpatient			
Facility ID:	22. Location of Specimen Collection		
□ ICU □ Emergency Room □ LTACH □ Surgery/OR □ Clinic/Doctor's office Facility ID: □ Radiology □ Dialysis center □ Autopsy □ Other inpatient □ Surgery □ Other (specify): □ Observational/clinical decision unit □ Unknown □ Other outpatient 23. Candida species from initial positive blood culture (check all that apply): □ Candida albicans (CA) □ Candida dubliniensis (CD) □ Candida, other (CO) specify:			— •
Surgery/OR ☐ Clinic/Doctor's office Facility ID: ☐ Radiology ☐ Dialysis center ☐ Autopsy ☐ Other inpatient ☐ Surgery ☐ Other (specify): ☐ Observational/clinical decision unit ☐ Unknown 23. Candida species from initial positive blood culture (check all that apply): ☐ Candida albicans (CA) ☐ Candida dubliniensis (CD) ☐ Candida, other (CO) specify:			
□ Radiology □ Dialysis center □ Autopsy □ Other inpatient □ Surgery □ Other (specify):			-
□ Other inpatient □ Surgery □ Other (specify):			
□ Observational/clinical decision unit □ Unknown □ Other outpatient □ Candida species from initial positive blood culture (check all that apply): □ Candida albicans (CA) □ Candida dubliniensis (CD) □ Candida, other (CO) specify:			☐ Autopsy
Other outpatient 23. Candida species from initial positive blood culture (check all that apply): Candida albicans (CA) Candida dubliniensis (CD) Candida, other (CO) specify:	Other inpatient	- .	
23. Candida species from initial positive blood culture (check all that apply): Candida albicans (CA) Candida dubliniensis (CD) Candida, other (CO) specify:			- Ondom
☐ Candida albicans (CA) ☐ Candida dubliniensis (CD) ☐ Candida, other (CO) specify:	23. <i>Candida</i> species from initial po		nat apply):
11 (G. 11)			
☐ Candida glabrata (CG) ☐ Candida krusei (CK) ☐ Candida species (CS) ☐ Candida paraprilogis (CP) ☐ Candida quilliarmendii (CGM) ☐ Pendina		•	
□ Candida parapsilosis (CP) □ Candida guilliermondii (CGM) □ Pending □ Candida tropicalis (CT)		<i>∟∟Сапииа guillermi</i>	orial (Cort) Penalty

Public reporting burden of this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

Version: Short Form 2024 Last Updated: 07/29/2023 Page **1** of **9**

		eck here 🗌 if no testing			1							
Date of culture	e Species	Drug	M	IC					etatio			
	1 □CA	Amphotericin B				□s []SDD	□I	□R	□NI	□ND	
	13 □CAU	Anidulafungin (Eraxis))			□s []SDD	□I	□R	□NI	□ND	
	2 □CG 3 □CP	Caspofungin (Cancidas	s)			□s []SDD	□I	□R	□NI	□ND	
	4 □CT 5 □CD	Fluconazole (Diflucan)			□s □]SDD	ΠI	□R	□NI	□ND	
	6 □CL	Flucytosine (5FC)				□s [SDD	□I	□R	□NI	□ND	
	7 □CK 8 □CGM	Itraconazole (Sporano	x)			□s □]SDD	□I	□R	□NI	□ND	
	9	Micafungin (Mycamine	e)			□s []SDD	□I	□R	□NI	□ND	
	11 □CS 12 □Pending	Posaconazole (Noxafil)			□s []SDD	□I	□R	□NI	□ND	
	12 Di chang	Voriconazole (Vfend)	1			□s []SDD	□I	□R	□NI	□ND	
		Amphotericin B				□s []SDD	□I	□R	□NI	□ND	
	1 □CA 13 □CAU	Anidulafungin (Eraxis))			□s []SDD	□I	□R	□NI	□ND	
	2 □CG	Caspofungin (Cancidas	s)			□s []SDD	□I	□R	□NI	□ND	
	3 □CP 4 □CT	Fluconazole (Diflucan)			□s []SDD	□I	□R	□NI	□ND	
	5 □CD 6 □CL	Flucytosine (5FC)				□s []SDD	□I	□R	□NI	□ND	
	7 □CK 8 □CGM	Itraconazole (Sporano	x)			□s []SDD		□R	□NI	□ND	
	9	Micafungin (Mycamine	e)			□s []SDD		□R	□NI	□ND	
	10 □CGN 11 □CS	Posaconazole (Noxafil)			□s []SDD		□R	□NI	□ND	
	12 Pending	Voriconazole (Vfend)				□s []SDD		□R	□NI	□ND	
		r test for <i>Candida</i> (e.g.,										
es 0 \(\text{No} \) 9 \(\text{U} \) Fyes, test type: \(\text{Log} \) esult: \(\text{Log} \)												
ny subsequent po	sitive <i>Candida</i> blo	ood cultures in the 29 da	ays after, n	ot inclu	uding tl	he DISC	? 1]Yes	0 🗆	No 9 □]Unknov	vn
, , ,		ositive <i>Candida</i> blood cultu	res and sele	t the sp	oecies:							
Drawn (<i>mm-dd-yy</i>)		s identified*		_	_	_	_			_	_	_
		□CAU □CG □CP □]CT □CD	□CL	□CK	□CGM	□co:			□CGN	I □cs	□Pe
		□CAU □CG □CP □]CT □CD	□CL	□CK	□CGM	□co:			□CGN	I □cs	□Pe
	□CA	□CAU □CG □CP □]CT □CD	□CL	□ск	□CGM	□co:			□CGN	ı □cs	□Pei
		□CAU □CG □CP □]CT □CD	□CL	□ск	□cgм	□co:			□CGN	ı □cs	□Pe

Version: Short Form 2024 Last Updated: 07/29/2023 Page **2** of **9**

State ID:D	ate of Incident Specimen	Collection (<i>mm-dd-yyyy</i>):	Surveillance Officer I	nitials
		e day of or in the 29 days after the DDISC)? 1 Yes 0 No 9 Unknown		es after this
27a. If yes, date of negative block	od culture:			
	resistant organism (MDRO	s the patient known to be colonized) (e.g., on contact precautions)? MI		
28a. If yes, specify organisms (E	Enter up to 3 pathogens):			
		ood cultures on the day of or in the		
1 □Yes 0 □No 9 □Unk	nown			
29a. If yes, additional organisms	(Enter up to 3 pathogens): _			_
30. Did the patient have any None Unknown	of the following types of i	nfection related to their <i>Candida</i> inf	ection? (check all that apply):	
☐Abdominal infection	☐Urinary tract infection	☐Pulmonary infection	□Endocarditis	
☐Hepatobiliary or pancreatic	☐Esophagitis	□Abscess	Septic emboli (specify	location):
☐Abscess (specify):	Oral/thrush	☐CNS infection (meningitis, brain abs	cess) Other (specify):	
☐Peritonitis/peritoneal fluid	☐ Osteomyelitis	□Eyes		
□Splenic	☐Skin /wound infection	☐ Endophthalmitis		
		☐ Chorioretinitis		
MEDICAL ENCOUNTERS				
31. Was the patient hospitali	ized on the day of or in the	e 6 days after the DISC? 1 Ye	es 0 No 9 Unknown	
31a. If yes,		□Unknown		
Hospital ID:		- 		
·				
31b. Was the patient transferred 1 □Yes 0 □No 9 □U	- ·			
If yes, enter up to two transfers	:			
Date of transfer:		Unknown Date of second transfer: _		_ Unknown
Hospital ID:	Unknown	Hospital ID:	Unknown	
31c. Where was the patient loc the DISC? (<i>Check one</i>)	ated prior to admission or, i	f not currently hospitalized, where was	s the patient located on the 3rd o	alendar day before
1 Private residence	4 □LTAC	CH 6 □Ind	carcerated	
2 Hospital inpatient	Facili	ity ID: 7 🔲 Ot	her (specify):	
Facility ID:	5 □Hom	oloss 0 🗆 III	nknown	
3 □LTCF	3 <u></u>	eless 9 🔲 OI	IKHOWH	
Facility ID:				
32. Was the patient in an ICI	J in the 14 days before, no	ot including the DISC?		
1 □Yes 0 □No 9 □U	Jnknown			
33. Was the patient in an ICI	J on the day of incident sp	ecimen collection or in the 13 days	after the DISC?	
1	Jnknown			
34. Did the patient receive d	lialysis or renal replaceme	nt therapy (RRT) in the 30 days bef	ore the DISC, not including the	DISC?
1 □Yes 0 □No 9 □U	Jnknown			
35. Patient outcome: 1 □Su	urvived 9 □Unknown	2 □Died		
Date of discharge:		Date of death:		
	Unknown		□Unknown	
Left against medical advice				
Version: Short Form 2024		Last Updated: 07/29/2023		Page 3 of 9

State ID: Date of Inc	ident Specimen Collection (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
35a. Discharged to: 0 □Not applicable (i.e. patient died, or not 1 □Private residence 2 □LTCF Facility ID: 3 □LTACH Facility ID:	6 ☐ Homeless 7 ☐ Incarcerated 9 ☐ Unknown	
(Check all that apply): □None □Ur □ B37 (candidiasis) Specify sub-code: □ Specify sub-code: □	<u> </u>	red) here) A41.9 (sepsis, unspecified organism) R65.2 (severe sepsis)
37a. If yes, date of discharge: Facility ID: 38. Overnight stay in LTACH in the 90 Facility ID:		0 □No 9 □Unknown
UNDERLYING CONDITIONS 40. Underlying conditions (Check all is Chronic Lung Disease	Chronic Liver Disease Chronic Liver Disease Chronic Liver Disease Ascites Cirrhosis Hepatic Encephalopathy Variceal Bleeding Hepatitis B, chronic Hepatitis C Treated, in SVR Current, chronic Hepatitis B, acute Malignancy Malignancy Malignancy, Solid Organ (non-metastatic) Malignancy, Solid Organ (metastatic) Meurologic Condition Cerebral palsy Chronic Cognitive Deficit Dementia Epilepsy/seizure/seizure disorder Multiple sclerosis Neuropathy Parkinson's disease Other (specify):	Plegias/Paralysis

Version: Short Form 2024 Last Updated: 07/29/2023 Page **4** of **9**

State ID:	Date of Incident Specimen Collectio	n (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
SOCIAL HISTORY			
41. Smoking (Check all that a	apply):	42. Alcohol Abuse:	
□None	□Tobacco	1 □Yes	
Unknown	☐E-nicotine delivery system	0	
Полиноми		9 □Unknown	
43. Other Substances (Check	k all that apply): □None □Unl	known	
43. Other Substances (enec.			Mode of Delivery (Check all that apply):
☐Marijuana (other than smoki	ng)	DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule I (e.g.	, Heroin)	□DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule II-IV (e.g., methadone, oxycodone)	□DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, NOS		□DUD or abuse	□IDU □Non-IDU □Unknown
☐Cocaine		□DUD or abuse	□IDU □Non-IDU □Unknown
☐ Methamphetamine		□DUD or abuse	□IDU □Non-IDU □Unknown
Other (specify):		DUD or abuse	□IDU □Non-IDU □Unknown
☐Unknown substance		□DUD or abuse	□IDU □Non-IDU □Unknown
			tment (MAT) for opioid use disorder?
1 □Yes 0 □No	8 N/A (patient not hospitalized or did	not have DUD) 9 □Ur	nknown
OTHER CONDITIONS			
45. For cases ≤ 1 year of ag	ge: Gestational age at birth:	wks 9 □Unknown ANI	D Birth weight: gms 9 Unknown
46. Chronic Dialysis:	Not on chronic dialysis Unknown	46a. If Hemodialysis, typ	e of vascular access:
Type: ☐ Hemodialysis ☐	Peritoneal	☐ AV fistula/graft ☐	Hemodialysis central line Unknown
47. Surgeries in the 90 days	s before, not including the DISC:	48. Pancreatitis in the	90 days before, not including the DISC:
☐Abdominal surgery (specify):	:	1 □Yes	
If yes: 1 ☐Open abdomen	n 0 □Laparoscopic 9 □Unknown	0	
□Non-abdominal surgery (spe	cify):	9 □Unknown	
□No surgery			
49. Did the patient have an	y ostomies of the gastrointestinal tr	act including ileostomy,	colostomy, etc. in the 30 calendar days before, not
including the DISC?			
1 □Yes 0 □No 9 □]Unknown		
50. Chronic Urinary Tract Pr		50a. If yes, did the patient before, not including the	nt have any urinary tract procedures in the 90 days DISC?
1 □Yes 0 □No	9 □Unknown	1	9 □Unknown
51. Was the patient neutro	penic in the 2 calendar days before,	not including the DISC?	
1]Unknown (no WBC days -2 or 0, or no c	_	
52. Did the patient have a C	CVC in the 2 calendar days before, n	ot including the DISC?	
1 □Yes 2 □No 3 □]Had CVC but can't find dates 9 □Unk	known	
If yes, was the central line	in place for > 2 calendar days: 1 \square Yes	0 □No 9 □Unkı	nown
52a. If yes, CVC type: (Check a	all that apply)		
□Non-tunneled CVCs	☐Implantable ports		Other (specify):
☐Tunneled CVCs	☐Peripherally inserte	ed central catheter (PICC)	□Unknown
52b. Were <u>all</u> CVCs removed or	changed in the 2 days before or in the	6 days after the DISC?	
1 □Yes	3 □CVC removed, but can't find d		9 □Unknown
2 No	5 Died or discharged before ind		
·	nidline catheter in the 2 calendar da]Unknown	ays before, not including	the DISC?
	-		

Version: Short Form 2024 Last Updated: 07/29/2023 Page **5** of **9**

State ID:	Date of Inciden	t Specimen Collection (mi	<i>m-dd-yyyy</i>):	Surveillance Officer Initials
	t have any of the followin	ng indwelling devices or o	ther devices present	in the 2 calendar days before, not including the
☐Urinary Catheter/	Device	Respiratory	Г	☐Gastrointestinal
☐Indwelling ur	ethral	□ET/NT		Abdominal drain (specify):
Suprapubic		☐Tracheostomy		Gastrostomy
		☐Invasive mechanic		
		oV-2 test result (moleculate the DISC or on the DISC?		ther confirmatory test, excluding serology) fro
1	o 9 □Unknown			
55a. If yes, date of	specimen collection for initial	positive SARS-CoV-2 test:		
Date:	9 🗌 Date Unknown			
55b. If yes, EIP CO				
		cterial medication in the	14 days before, not in	cluding the DISC?
1 □Yes 0 □No	9 □Unknown			
-		eroids in the 30 days befo	ore, not including the	DISC?
1 □Yes 0 □No				
57a. If yes, what wa	s the reason steroids were a	administered? (check all that a	apply)	
	given as an outpatient med			d-
	given, prior to <i>Candida</i> DISG given as part of treatment/r	C, during hospitalization asso	ciated with candidemia (episode
☐ None of the		nunagement for COVID 13		
58. Did the patien	t receive total parentera	nutrition (TPN) in the 14	davs before, not incl	uding the DISC?
1	-		,.	-
59. Did the patien	t receive systemic antifu	ngal medication on the da	ay of or in the 13 days	before the DISC?
1 □Yes (if Yes, fill o	out question 66) 0 🗆 No	o 9 □Unknown		
60. Was the patie	nt administered systemic	antifungal medication af	ter, not including the	DISC?
1 □Yes (if Yes, fill o	out question 66) 0 □No	o 9 □Unknown		
61. If antifungal r	nedication was not given	to treat current candiden	nia infection, what wa	as the reason?
1 □Patient died bef	ore culture result available to	o clinicians 5 🗆	Other reason documen	ted in medical records, specify:
2 □Comfort care or	nly measures were instituted	6 🗆]Patient refused treatme	ent against medical advice
3 □Patient dischard	jed before culture result avai	ilable to clinician 9 [Unknown	
4 ☐Medical records	indicated culture result not		_	
contaminated	TE ANY A	NTIFUNGAL MEDICATION	WAS GIVEN COMPLI	ETE NEXT PAGE
OTHER	I ANI AI	TITI ONGAL MEDICATION	WAS GIVEN, COMPE	TE NEXT PAGE:
OTHER				
62. Does the char infection?	: indicate that the incider	it specimen was considere	ed a contaminant or v	was considered to not be indicative of true
1	o 9 Unknown			
		fectious disease physicia	n on the day of the DI	SC or within the 6 days after the DISC?
			•	•
1 □Yes 0 □N	t have an echocardiogram	n (ECHO), including trans	thoracic (TTE) or trar	sesophogeal (TEE), on the day of or 13 days
64. Did the patien				
64. Did the patien after the DISC?	-			
64. Did the patien	-			
64. Did the patien after the DISC? 1 Yes 0 N	o 9 □Unknown	opic eye exam on the day	of or 13 days after the	e DISC?

Version: Short Form 2024 Last Updated: 07/29/2023 Page **6** of **9**

lcet, AmBio Iulafungin (pofungin (C	any IV formulation (Amphotec, Amphoc some, etc.)=AMBIV Eraxis)=ANF ancidas)=CAS	Fl Is It	uconazole (Diflucan)=FLC ucytosine (5FC)=5FC avuconazole (cresemba)=ISU raconazole (Sporanox)=ITC icafungin (Mycamine)=MFG	Pc Ul	cher=OTH osaconazole (Noxafil)=PSC NKNOWN DRUG=UNK oriconazole (Vfend)=VRC	
ANTIFUNG a. Drug Abbrev	GAL MEDICATION b. First date given (mm-dd-yyyy)	c. Date start unknown	d. Last date given (mm-dd-yyyy)	e. Date stop unknown	f. Indication	g. Reason for stoppii (if applicable)*
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	

State ID: ______ Date of Incident Specimen Collection (mm-dd-yyyy): ___-___ Surveillance Officer Initials _____

Version: Short Form 2024 Last Updated: 07/29/2023 Page **7** of **9**

		AECT recults for a	dditional	Candida isolatos
ntifungal sussenti	hiliby tooting (ch	AFST results for a		
Date of culture	Species	eck here if no testing do	MIC	·
Date of culture	1 DCA	Drug Amphotericin B	MIC	Interpretation ☐S ☐SDD ☐I ☐R ☐NI ☐ND
	13 □CAU	· ·		
	2 □CG	Anidulafungin (Eraxis)		
	3 □CP 4 □CT	Caspofungin (Cancidas)		
	5 □CD	Fluconazole (Diflucan)		
	6 □CL	Flucytosine (5FC)		
	7 □CK 8 □CGM	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	9	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	10 □CGN 11 □CS	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 □CS 12 □Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
	1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND
	13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	3 □CP 4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	5 □CD	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	6 □CL 7 □CK	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	8 □CGM	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	9	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 CS 12 Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
ntifungal suscepti	bility testing (ch	eck here \square if no testing do	ne/no test re	ports available):
Date of culture	Species	Drug	MIC	Interpretation
	1	Amphotericin B		□S □SDD □I □R □NI □ND
	113 ICAH			
	13 □CAU 2 □CG	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP	Anidulafungin (Eraxis) Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND □S □SDD □I □R □NI □ND
	2 □CG 3 □CP 4 □CT			
	2 □CG 3 □CP 4 □CT 5 □CD 6 □CL	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan)		S SDD I R NI ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC)		□S □SDD □I □R □NI □ND □S □SDD □I □R □NI □ND □S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend)		□S □SDD □I □R □NI □ND □S □SDD □I □R □NI □ND
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B		S
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis)		S
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas)		S
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan)		S
	2	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC) Itraconazole (Sporanox) Micafungin (Mycamine) Posaconazole (Noxafil) Voriconazole (Vfend) Amphotericin B Anidulafungin (Eraxis) Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC)		S

Version: Short Form 2024 Last Updated: 07/29/2023 Page **8** of **9**

State ID:	Date of I	ncident Specimen Collectio	n (<i>mm-dd-yyyy</i>):		s	Survei	llance	Officer	Initials _	
	10 □CGN 11 □CS 12 □Pending	Voriconazole (Vfend)		□s	□SDD		□R	□NI	□ND	
Versi	on: Short Form 2024	Last Up	odated: 07/29/2023						Page 9	of 9